Preclinical Evidence for the Effectiveness of Mesenchymal Stromal Cells for Diabetic Cardiomyopathy: A Systematic Review and Meta-analysis

被引:1
|
作者
Liu, Boxin [1 ,2 ]
Zhang, Jinyu [1 ,2 ]
Zhou, Zijing [1 ,2 ]
Feng, Baofeng [1 ,2 ]
He, Jingjing [1 ,2 ]
Yan, Wei [1 ,2 ]
Zhou, Xinghong [1 ,2 ]
Amponsah, Asiamah Ernest [1 ]
Guo, Ruiyun [1 ,2 ]
Du, Xiaofeng [1 ,2 ]
Liu, Xin [1 ,2 ]
Cui, Huixian [1 ,2 ,4 ]
O'Brien, Timothy [1 ,2 ,3 ]
Ma, Jun [1 ,2 ,4 ]
机构
[1] Hebei Med Univ, Hebei Med Univ Natl Univ Ireland Galway Stem Cell, Shijiazhuang 050017, Hebei, Peoples R China
[2] Hebei Res Ctr Stem Cell Med Translat Engn, Shijiazhuang 050017, Hebei, Peoples R China
[3] Natl Univ Ireland Galway, Regenerat Med Inst, Sch Med, Galway, Ireland
[4] Hebei Med Univ, Human Anat Dept, Shijiazhuang 050017, Hebei, Peoples R China
关键词
Diabetes cardiomyopathy; mesenchymal stromal cells; meta-analysis; preclinical studies; cardiovascular disease; human health; STEM-CELLS; HEART-FAILURE; CONTROLLED-TRIAL; DYSFUNCTION; EFFICACY; MECHANISMS;
D O I
10.2174/1574888X18666230510111302
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background: Diabetic cardiomyopathy (DCM) is a complication of diabetes mellitus that endangers human health. DCM results in cardiac dysfunction, which eventually progresses to heart failure. Mesenchymal stromal cells (MSCs), a type of multipotent stem cell, have shown promising therapeutic effects in various cardiovascular diseases and diabetic complications in preclinical studies due to their immunomodulatory and regenerative abilities. However, there is still a lack of evidence to summarize the effectiveness of MSCs in the treatment of DCM. Therefore, a meta-analysis and systematic review are warranted to evaluate the therapeutic potential of MSCs for DCM in preclinical studies.Methods: A comprehensive literature search in English or Chinese was conducted in PubMed, EMBASE, web of Science, Cochrane Library, and China National Knowledge Internet from inception to June 30, 2022. The summarized outcomes included echocardiography, morphology, and pathology. Data were independently extracted and analyzed by two authors. The software we adopted was Review Manager5.4.1. This systematic review was written in compliance with PRISMA 2020 and the review protocol was registered on PROSPERO, registration no. CRD42022350032.<br />Results: We included 20 studies in our meta-analysis to examine the efficacy of MSCs in the treatment of DCM. The MSC-treated group showed a statistically significant effect on left ventricular ejection fraction (WMD=12.61, 95% CI 4.32 to 20.90, P=0.003) and short axis fractional shortening (WMD=6.84, 95% CI 4.09 to 9.59, P < 0.00001). The overall effects on the ratio of early to late diastolic mitral annular velocity, left ventricular end-diastolic pressure, maximum positive pressure development, maximum negative pressure development, left ventricular relaxation time constant, heart weight to body weight ratio, fibrosis area, and arteriole density were analyzed, suggesting that MSCs represent an effective therapy for the treatment of DCM.<br />Conclusion: Our results suggest a therapeutic role for MSCs in the treatment of DCM, and these results provide support for the use of MSCs in clinical trials of patients with DCM.
引用
收藏
页码:220 / 233
页数:14
相关论文
共 50 条
  • [21] Effects of mesenchymal stem cells in renovascular disease of preclinical and clinical studies: a systematic review and meta-analysis
    Hong-Shen Wang
    Ming-Yu Yi
    Xi Wu
    Qian Liu
    Ying-Hao Deng
    Ting Wu
    Lin Wang
    Yi-Xin Kang
    Xiao-Qin Luo
    Ping Yan
    Mei Wang
    Shao-Bin Duan
    Scientific Reports, 12
  • [22] Effects of Mesenchymal Stromal Cells on Diabetic Cardiomyopathy
    Van Linthout, S.
    Spillmann, F.
    Schultheiss, H. -P.
    Tschoepe, C.
    CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (30) : 3341 - 3347
  • [23] Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials
    Lalu, Manoj M.
    McIntyre, Lauralyn
    Pugliese, Christina
    Fergusson, Dean
    Winston, Brent W.
    Marshall, John C.
    Granton, John
    Stewart, Duncan J.
    PLOS ONE, 2012, 7 (10):
  • [24] Efficacy of umbilical cord mesenchymal stromal cells for COVID-19: A systematic review and meta-analysis
    Yang, Cong-wen
    Chen, Ru-dong
    Zhu, Qing-run
    Han, Shi-jie
    Kuang, Ming-jie
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [25] Efficacy of Mesenchymal Stromal Cells for Fistula Treatment of Crohn’s Disease: A Systematic Review and Meta-Analysis
    Yantian Cao
    Zhen Ding
    Chaoqun Han
    Huiying Shi
    Lianlian Cui
    Rong Lin
    Digestive Diseases and Sciences, 2017, 62 : 851 - 860
  • [26] Therapeutic efficacy of mesenchymal stromal cells and secretome in pulmonary arterial hypertension: A systematic review and meta-analysis
    Muhammad, Suleiman Alhaji
    Abbas, Abdullahi Yahaya
    Saidu, Yusuf
    Fakurazi, Sharida
    Bilbis, Lawal Suleiman
    BIOCHIMIE, 2020, 168 : 156 - 168
  • [27] Effect of mesenchymal stromal cells transplantation on the outcomes of patients with knee osteoarthritis: A systematic review and meta-analysis
    Xie, Rong-hui
    Gong, Shi-guo
    Song, Jiao
    Wu, Ping-ping
    Hu, Wen-Long
    JOURNAL OF ORTHOPAEDIC RESEARCH, 2024, 42 (04) : 753 - 768
  • [28] Efficacy of Mesenchymal Stromal Cells for Fistula Treatment of Crohn's Disease: A Systematic Review and Meta-Analysis
    Cao, Yantian
    Ding, Zhen
    Han, Chaoqun
    Shi, Huiying
    Cui, Lianlian
    Lin, Rong
    DIGESTIVE DISEASES AND SCIENCES, 2017, 62 (04) : 851 - 860
  • [29] Effectiveness of health coaching on diabetic patients: A systematic review and meta-analysis
    Radwan, Nashwa Mohamed
    Al Khashan, Hisham
    Alamri, Fahad
    El Olemy, Ahmed Tofek
    TRADITIONAL MEDICINE RESEARCH, 2019, 4 (06): : 314 - 325
  • [30] Systematic review and meta-analysis of preclinical studies
    Ineichen, Benjamin Victor
    Held, Ulrike
    Salanti, Georgia
    Macleod, Malcolm Robert
    Wever, Kimberley Elaine
    NATURE REVIEWS METHODS PRIMERS, 2024, 4 (01):